PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : T

Records returned : 159 (on 17 May 2024 at 10:33:34).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Tacalcitol
No Information Returned
Tacrolimus
No Information Returned
07.04.01
07.04.05
Tadalafil
Erectile dysfunction
Green (see narrative)
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Sildenafil is 1st line. Tadalafil (10mg and 20mg) is an alternative. Note - Once daily tadalafil (2.5mg and 5mg) is non-formulary.
07.04.01
07.04.05
Tadalafil
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
07.04.01
07.04.05
Tadalafil
Erectile dysfunction
Non Formulary
Formulations :
  • ONCE DAILY
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Once daily tadalafil (2.5mg and 5mg) is non-formulary. Sildenafil is 1st line. Tadalafil (10mg and 20mg) is an alternative.
07.04.01
07.04.05
Tadalafil
Erectile dysfunction combination therapy
Non Formulary
Formulations :
  • Tablets
  • ONCE DAILY
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Tadalafil (Vasodilator Antihypertensive)
No Information Returned
Tafamidis
No Information Returned
Tafluprost
No Information Returned
Tafluprost and timolol
No Information Returned
Talc purified
No Information Returned
Tamoxifen citrate
No Information Returned
07.04.01
Tamsulosin and dutasteride hydrochloride
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
07.04.01
07.04.02
Tamsulosin hydrochloride
Benign prostatic hyperplasia
Green
Formulations :
  • Modified release capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Preferred
07.04.01
07.04.02
Tamsulosin hydrochloride
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
Use modified release capsules
07.04.01
Tamsulosin with solifenacin
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
04.07.02
Tapentadol hydrochloride
Pain (non-malignant)
Blue
Formulations :
  • Modified release tablets
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
R
Important
Only on recommendation by a pain specialist for patients not responding to / not tolerating morphine or oxycodone
Tars
No Information Returned
Taurine
No Information Returned
Taurolidine
No Information Returned
Tazarotene
No Information Returned
Tedizolid
No Information Returned
Tegafur
No Information Returned
Tegafur/gimeracil/oteracil
No Information Returned
Teicoplanin
No Information Returned
Telaprevir
No Information Returned
Telbivudine
No Information Returned
Telithromycin
No Information Returned
Telmisartan
No Information Returned
Telmisartan with diuretic
No Information Returned
Telotristat ethyl
No Information Returned
Temazepam
No Information Returned
Temocillin sodium
No Information Returned
Temoporfin
No Information Returned
Temozolomide
No Information Returned
Temsirolimus
No Information Returned
Tenecteplase
No Information Returned
Tenofovir alafenamide
No Information Returned
Tenofovir disoproxil
No Information Returned
Tenoxicam
No Information Returned
07.04.01
Terazosin hydrochloride
Benign prostatic hyperplasia
Green (see narrative)
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted for patients with renal or hepatic failure
Terbinafine hydrochloride
No Information Returned
07.01.03
Terbutaline sulfate
Delay of premature labour
Red
Formulations :
  • Infusion
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
R
Important
Under specialist supervision in hospital
Terbutaline sulphate
No Information Returned
Terfenadine
No Information Returned
08.02.04
Teriflunomide
Multiple sclerosis
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NHSE
BlueTeq
NICE
Teriparatide
No Information Returned
Terlipressin
No Information Returned
Terpin hydrate
No Information Returned
Testolactone
No Information Returned
06.04.02
Testosterone
Low sexual desire in menopausal women
Green
Formulations :
  • Gel
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically as "Testosterone 2% transdermal gel 60g"
06.04.02
Testosterone
Transgender Health - adults
Amber
Formulations :
  • Gel
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
06.04.02
Testosterone
Low sexual desire in menopausal women
Non Formulary
Formulations :
  • Cream
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
U
Important
Androfeme is unlicensed in the UK. Other products can be used off-label
06.04.02
Testosterone
Transgender Health - Children & Young People
See narrative
Formulations :
  • Gel
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Testosterone enantate
No Information Returned
Testosterone esters
No Information Returned
Testosterone propionate
No Information Returned
Testosterone undecanoate
No Information Returned
Tetanus
No Information Returned
Tetanus immunoglobulin
No Information Returned
04.09.03
Tetrabenazine
Movement disorders
Blue
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Includes choreas, Huntington's chorea, dyskinesia, hemiballismus
Tetracaine
No Information Returned
Tetracaine hydrochloride
No Information Returned
Tetracosactide
No Information Returned
Tetracycline
No Information Returned
Tetracycline combined preparations
No Information Returned
Tetracycline hydrochloride
No Information Returned
Tezacaftor/ivacaftor
No Information Returned
Thalidomide (Antileprotic)
No Information Returned
Thalidomide (Immunomodulating)
No Information Returned
Theophylline
No Information Returned
09.06.02
Thiamine hydrochloride
post Bariatric surgery
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
For supplementation in cases of concern regarding deficiency post-surgery or for prevention of Wernicke’s encephalopathy
Thiopental sodium
No Information Returned
Thioridazine
No Information Returned
Thymol
No Information Returned
Thyrotropin alfa
No Information Returned
Tiabendazole
No Information Returned
04.08.01
Tiagabine
Epilepsy
Non Formulary
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Tiaprofenic acid
No Information Returned
Tibolone
No Information Returned
Ticagrelor
No Information Returned
Ticarcillin with clavulanic acid
No Information Returned
Tick-borne encephalitis vaccine
No Information Returned
Ticlopidine hydrochloride
No Information Returned
Tigecycline
No Information Returned
13.05.02
13.05.03
Tildrakizumab
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Tiludronic acid
No Information Returned
Timolol
No Information Returned
Timolol and bimatoprost
No Information Returned
Timolol and brimonidine
No Information Returned
Timolol and travoprost
No Information Returned
Timolol with diuretic
No Information Returned
Timothy grass pollen allergen extract
No Information Returned
Tinidazole
No Information Returned
Tinzaparin sodium
No Information Returned
Tioconazole
No Information Returned
Tioguanine
No Information Returned
Tiopronin
No Information Returned
Tiotropium bromide
No Information Returned
Tiotropium bromide/olodaterol
No Information Returned
Tipranavir
No Information Returned
Tirbanibulin
No Information Returned
06.01.02
Tirzepatide
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
3rd line where dulaglutide or semaglutide are unsuitable / unavailable
Titanium dioxide
No Information Returned
Tivozanib
No Information Returned
10.02.02
Tizanidine hydrochloride
Spasticity and muscle spasm
Blue
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Specialist to retain prescribing for first 4 months. Monitor liver function.
Tobramycin
No Information Returned
10.01.03
Tocilizumab
Rheumatoid arthritis
Red
Formulations :
  • Intravenous infusion
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Severe disease only
10.01.03
Tocilizumab
Any paediatric use
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
10.01.03
Tocilizumab
Arteritis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
Tocofersolan
No Information Returned
Tocopheryl acetate
No Information Returned
01.05.03
10.01.03
Tofacitinib
Ulcerative colitis
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
Tofacitinib
Psoriatic arthritis
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
SA
ICB
BlueTeq
NICE
01.05.03
10.01.03
Tofacitinib
Rheumatoid arthritis
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
SA
ICB
BlueTeq
NICE
Important
Severe disease only
01.05.03
10.01.03
Tofacitinib
Ankylosing spondylitis
Red
Formulations :
  • Tablets
  • Tablets (slow release)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
Tofacitinib
Any paediatric use
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
Tolbutamide
No Information Returned
04.09.01
Tolcapone
Parkinson's disease
Amber
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Tolfenamic acid
No Information Returned
Tolnaftate
No Information Returned
07.04.02
Tolterodine
Overactive bladder (adults)
Green (see narrative)
Formulations :
  • Immediate release tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
1st line in patients with renal impairment
07.04.02
Tolterodine
Overactive bladder (adults)
Non Formulary
Formulations :
  • Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Switch to solifenacin (or formulary alternative) recommended
Tolvaptan
No Information Returned
04.07.04
04.08.01
Topiramate
Migraine (prevention)
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
04.07.04
04.08.01
Topiramate
Migraine (prevention)
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
Capsules (Sprinkle) reserved for use in patients who cannot swallow tablets.
04.07.04
04.08.01
Topiramate
Migraine (prevention)
Green (see narrative)
Formulations :
  • Oral suspension
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
Only use where patient cannot swallow tablets or capsules (sprinkle) are not suitable.
04.07.04
04.08.01
Topiramate
Epilepsy
Blue
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
Capsules (Sprinkle) reserved for use in patients who cannot swallow tablets. Liquid reserved for patients who cannot swallow tablets or capsules
Topotecan
No Information Returned
Torasemide
No Information Returned
Toremifene citrate
No Information Returned
Trabectedin
No Information Returned
13.05.03
Tralokinumab
Atopic dermatitis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
SA
ICB
BlueTeq
NICE
04.07.02
Tramadol hydrochloride
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Capsules
  • Soluble tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Important
NICE CG 173 Consider tramadol only if acute rescue therapy is needed. Prescribe a short course (2-4 weeks on an acute script) and review at least every 3 months.
04.07.02
Tramadol hydrochloride
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Modified release capsules
  • Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Important
NICE CG 173 Consider tramadol only if acute rescue therapy is needed. Prescribe a short course (2-4 weeks on an acute script) and review at least every 3 months.
MR preparations to be prescribed by brand. Marol MR tablets are the locally preferred brand for primary care.
04.07.02
Tramadol hydrochloride
Pain (non-malignant)
Green (see narrative)
Formulations :
  • Capsules
  • Modified release capsules
  • Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Important
Modified-release preparations to be prescribed by brand
04.07.02
Tramadol with paracetamol
Pain (non-malignant)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
CD
Trametinib
No Information Returned
Trandolapril
No Information Returned
Trandolapril with calcium channel blocker
No Information Returned
Tranexamic acid
No Information Returned
Tranylcypromine sulfate
No Information Returned
Trastuzumab
No Information Returned
Travoprost
No Information Returned
Trazodone hydrochloride
No Information Returned
Treosulfan
No Information Returned
Tretinoin
No Information Returned
10.01.02
12.01.01
Triamcinolone acetonide
Soft tissue and joint disorders
Green
Formulations :
  • Intra-articular injection
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
10.01.02
Triamcinolone hexacetonide
Soft tissue and joint disorders
Green
Formulations :
  • Intra-articular injection
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Triamterene
No Information Returned
Triamterene with loop diuretics
No Information Returned
Triamterene with thiazides
No Information Returned
Trichloroacetic acid
No Information Returned
Triclofos sodium
No Information Returned
Triclosan
No Information Returned
Trientine dihydrochloride
No Information Returned
Trientine tetrahydrochloride
No Information Returned
Trifluoperazine
No Information Returned
Trifluridine (Antivirals)
No Information Returned
Trifluridine/tipiracil
No Information Returned
04.09.02
Trihexyphenidyl hydrochloride
Dystonia
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Paediatrics only. Transfer to primary care only after initiation and stabilisation.
04.09.02
Trihexyphenidyl hydrochloride
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Trilostane
No Information Returned
Trimetaphan camsilate
No Information Returned
Trimetazidine hydrochloride
No Information Returned
Trimethoprim
No Information Returned
Trimipramine maleate
No Information Returned
Tripotassium dicitratobismuthate
No Information Returned
06.07.02
08.03.04
Triptorelin
Transgender Health - adults
Amber
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
06.07.02
08.03.04
Triptorelin
Transgender Health - Children & Young People
See narrative
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Triptorelin acetate
No Information Returned
Triptorelin embonate
No Information Returned
Trisodium edetate
No Information Returned
Tropicamide
No Information Returned
Tropisetron
No Information Returned
07.04.02
Trospium chloride
Overactive bladder (adults)
Green (see narrative)
Formulations :
  • Immediate release tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Alternative 1st line in patients where anticholinergic burden is a problem or on medicines that interact.
07.04.02
Trospium chloride
Overactive bladder (adults)
Green (see narrative)
Formulations :
  • Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
2nd line in patients where anticholinergic burden is a problem or on medicines that interact.
04.03.04
Tryptophan
Treatment resistant depression
N/A
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD2
Turpentine oil
No Information Returned
Tyloxapol
No Information Returned
Typhoid
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More